Study identifies CAR3 as a key protein in bone formation

Researchers at Wuhan University found that carbonic anhydrase III helps osteoblasts mineralize collagen and strengthen bone, pointing to a possible new approach for treating fractures and osteoporosis. The mouse study also showed that CAR3-functionalized scaffolds improved bone repair after injury.

Why it matters: - CAR3 could become a target for therapies aimed at strengthening bone and improving repair after injury. - The findings may help explain how osteoblasts build mineralized bone tissue and why bone formation breaks down in disorders such as osteoporosis. - CAR3-based biomaterials could support regenerative strategies for fractures and other skeletal defects.

What happened: - A research team led by Dr. Fangfang Song and Professor Yufeng Zhang at Wuhan University identified carbonic anhydrase III, or CAR3, as a previously unrecognized protein involved in healthy bone development and regeneration. - The study was published May 19, 2026, in the International Journal of Oral Science. - The research used single-cell RNA sequencing, genetically modified mice and bone repair models.

The details: - CAR3 helps osteoblasts mineralize collagen and strengthen bone tissue by interacting with collagen and bone sialoprotein, or BSP. - The team found that RUNX2, a master bone-formation transcription factor, directly regulates Car3 during osteoblast differentiation. - CAR3 forms a molecular complex with collagen type I alpha 1, or COL1A1, and recruits BSP. - That ternary complex promotes collagen intrafibrillar mineralization, a process needed for strong, properly mineralized bone. - Single-cell RNA sequencing showed that Car3 was highly activated in osteoblast-lineage cells during early embryonic cranial development, especially between embryonic days 14.5 and 15.5. - Car3 expression also appeared in limb, rib and spinal bones. - In young mice, Car3 expression was closely associated with collagen-producing osteoblasts. - In aged mice, Car3 expression shifted toward adipocytes. - Mice lacking CAR3 developed impaired osteoblast activity, defective collagen mineralization, reduced bone formation and lower bone density. - Early femur development in the CAR3-deficient mice remained largely unaffected. - In bone defect models, recombinant CAR3-functionalized collagen scaffolds increased new bone formation, bone volume, osteoblast recruitment and bone matrix mineralization after eight weeks.

Between the lines: - The study adds CAR3 to the short list of molecules that appear to control the jump from collagen production to hard, mineralized bone. - The age-related shift in Car3 expression toward adipocytes suggests CAR3 may be tied not only to bone building, but also to changes in skeletal stem cell behavior over time. - The scaffold results point to a practical use case: CAR3 may be valuable not just as a biological marker, but as a component in engineered bone repair materials.

What's next: - The researchers said CAR3-related effects on osteoblast differentiation could be harnessed to treat bone disorders. - Future work will likely test whether CAR3-based biomaterials can translate beyond mice into broader regenerative medicine applications. - The study points to possible use in osteoporosis, fractures and other bone disorders.

The bottom line: - CAR3 looks like a newly identified driver of bone mineralization and repair, with early evidence that it could help power next-generation bone-healing treatments.